GlobeNewswire by notified

CFO Barbara Plucnar Jensen to leave Tryg A/S. Allan Kragh Thaysen has been appointed CFO and member of the Executive Board

Share


Barbara Plucnar Jensen, Chief Financial Officer (CFO) and member of the Executive Board, will leave Tryg A/S by mutual agreement. Effective November 2, 2023, Allan Kragh Thaysen (46), Tryg’s SVP of Group Finance for the past five years, has been appointed as the new CFO and as a member of Tryg’s Executive Board.   

Barbara Plucnar Jensen has been part of Tryg’s executive management since 2019. Her unique skills within corporate finance have been instrumental during the acquisition and financing of RSA’s Scandinavian activities and the share issue that followed.

Group CEO Johan Kirstein Brammer expressed his appreciation of Barbara’s contributions during a decisive time in the history of the Tryg Group.

”Barbara has made a significant impact on the Group that we have become. She has advanced our compliance and governance practices, driven the anchoring of ESG across the business, and not least played an essential role in transforming the Group into Scandinavia’s largest non-life insurance company. Her experience within corporate finance and M&A has been a valuable asset throughout this process. As the integration of the recently acquired businesses draws to an end, the enlarged Group is now entering a new phase with a renewed focus on optimizing our insurance operations. This calls for a different CFO profile.”

Barbara Plucnar Jensen says:

”I am proud to have contributed to the transformation that Tryg has undergone in the past 4 years – becoming Scandinavia’s largest non-life insurer. The assignment I was hired for has been successfully completed, and the time has come for Tryg to start a new chapter with a new CFO. The timing is right and I will now take the opportunity to start planning the next steps in my career.”

An internal successor, Allan Kragh Thaysen, has been chosen to assume the position as Group CFO. Allan brings with him 18 years of experience in the insurance industry and has reported to Barbara Plucnar Jensen for the past five years as SVP of Group Finance. He has worked closely with the Executive Board and played an integral part in the acquisition of RSA’s Scandinavian businesses.

Group CEO Johan Kirstein Brammer elaborates:

”I am proud to see that, once again, we can benefit from a strong focus on succession planning. Allan’s talent and potential has been widely recognized in the organization for a long time. We are pleased that we have been able to appoint yet another internal candidate for a position of this importance. Allan is a skilled leader and a leading light in his field of expertise. The combination of Allan’s professional skills and solid experience within insurance – both inside and outside of Tryg Group – makes him the most suitable candidate for the job in both short and long term.”

The Executive Board of Tryg A/S now consists of Chief Executive Officer Johan Kirstein Brammer, Chief Financial Officer Allan Kragh Thaysen, Chief Operational Officer Lars Bonde, Chief Commercial Officer Alexandra Bastkær Winther, and Chief Technical Officer Mikael Kärrsten. 

About Allan Kragh Thaysen

Allan Kragh Thaysen (46) has an HD in Accounting and an MSc in Business Economics and Auditing from Copenhagen Business School. He will bring to his role as CFO many years of experience in the financial sector and within non-life insurance. Allan started his career as an accountant at Deloitte from 1998-2005, after which he joined the Norwegian company Gjensidige, where he became CFO for the Danish and Swedish portion of the business from 2010 to 2018 before coming to Tryg. For the past 5 years he has delivered strong results in his position as SVP of Group Finance and played an integral part in the acquisition of RSA’s Scandinavian businesses, Trygg-Hansa and Codan Norway.

Financial targets for 2024

All financial targets for 2024 are unchanged including the insurance service result between DKK 7.2 and 7.6bn and a Combined ratio target at or below 82.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Scatec at COP28: Accelerating renewable energy transition from Egypt to South Africa2.12.2023 14:01:22 CET | Press release

Dubai, 2 December 2023: This week, Scatec ASA, a leading renewable energy company, is actively engaging in the UN Climate Change Conference in Dubai (COP28). Our focus is to underscore renewable energy as an unequivocal solution to climate change and emphasise the critical need for increased green energy investments in emerging markets. COP28 serves as a pivotal platform for global stakeholders to reinforce commitments aimed at averting catastrophic consequences of climate change. Scatec aligns with climate experts in stressing the urgency of the situation and the imperative to continue advancing towards the objectives outlined in the Paris Agreement. There's no time to waste, and collective progress is crucial for safeguarding our planet's future. “We are at COP28 to highlight the key role renewable energy must play in our energy future, "At COP28, our focus is on underscoring the crucial role renewable energy must assume in shaping our energy future, particularly in emerging markets,

Unplugged Performance Introduces UP INVINCIBLE®: A Game-Changer for Tesla Cybertruck Enthusiasts2.12.2023 05:06:20 CET | Press release

HAWTHORNE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Unplugged Performance, the industry leader in performance upgrades for Tesla vehicles, debuts a new chapter in Tesla tuning with the arrival of their UP INVINCIBLE® product line. UP INVINCIBLE® is tailored exclusively for Tesla Cybertruck owners who want to push the limits of on-road and off-road performance. The unveiling took place at Unplugged Performance’s celebratory afterparty for Tesla's highly anticipated Cybertruck delivery event on November 30th. Hosted at the company's headquarters in Hawthorne, California, neighboring Tesla Design Studio, SpaceX, and Starlink, the event drew a capacity crowd, reflecting the immense enthusiasm for this innovative product range. UP INVINCIBLE® represents a concerted effort to harness and amplify the rugged DNA of the Cybertruck, making it even more robust and capable in a variety of challenging environments. During the event, Ben Schaffer, CEO of Unplugged Performance, presented an extensiv

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA2.12.2023 04:39:35 CET | Press release

SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC. This NCE application was submitted through Project Orbis, an initiative of

Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu